FDA tightens warnings for Astellas stress agents but generics a bigger threat?
This article was originally published in Scrip
Executive Summary
Two cardiac stress test agents marketed in the US by Astellas Pharma are the subject of a new warning from the FDA over a "rare but serious risk of heart attack and death" in certain patients, prompted by recent reports of serious adverse events.